NASDAQ: BTTXBetter Therapeutics Inc Stock
$0.73+0.00 (+0%)
Updated Jun 5, 2023
BTTX Price
$0.73
Fair Value Price
$1.40
Market Cap
$23.16M
52 Week Low
$0.59
52 Week High
$2.80
P/E
-0.44x
P/B
-2.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$39.46M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.3
Operating Cash Flow
-$29M
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BTTX Overview
Better Therapeutics, Inc. is developing a cognitive-behavioral therapies to address the root causes of cardiometabolic diseases such type 2 diabetes. Its treatments target the cognitive structures, behavioral routines, emotional patterns, and coping skills that underlie culturally specific eating behaviors. Better Therapeutics was founded in 2015 and is headquartered in San Francisco, CA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BTTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BTTX ($0.73) is undervalued by 47.95% relative to our estimate of its Fair Value price of $1.40 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BTTX ($0.73) is significantly undervalued by 47.95% relative to our estimate of its Fair Value price of $1.40 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BTTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BTTX due diligence checks available for Premium users.
Be the first to know about important BTTX news, forecast changes, insider trades & much more!
BTTX News
Valuation
BTTX fair value
Fair Value of BTTX stock based on Discounted Cash Flow (DCF)
Price
$0.73
Fair Value
$1.40
Undervalued by
47.95%
BTTX ($0.73) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BTTX ($0.73) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BTTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BTTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.44x
Industry
11.59x
Market
53.21x
BTTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.36x
Industry
5.21x
BTTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.4M
Profit Margin
0%
BTTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.8M
Liabilities
$22.6M
Debt to equity
-2.3
BTTX's short-term liabilities ($13.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BTTX's long-term liabilities ($9.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BTTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BTTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.7M
Investing
-$521.0k
Financing
-$435.0k
BTTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BTTX vs Biotech Stocks
Better Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.